Bachem Holding BANB.CH | SWISS SE Exch | Medical-Biomed/Biotech | MktCap CHF6.48B Sales CHF577.32M | Shares 75M Float 32M | EPS Due in 58 Days (e)

41585952021
EPS Rank 93

bachem.com — Bubendorf, SWITZERLAND Inc 2003 — MGMT owns --

Bachem Holding AG engages in the provision of peptides and oligonucleotides. It operates through the Europe Asia and North America geographical segments. It offers project management, research grade production, catalog peptides, peptide NCES, and commercial NCES. The company was founded in 2003 and is headquartered in Bubendorf, Switzerland. LESS

ANNUAL - DEC END	2015	2016	2017	2018	2019	2020	2021	2022	2023
EPS CHF	0.47	0.61	0.62	0.69	0.78	1.12	1.62	1.37	1.50
CASH FLOW/SHR CHF	0.91	0.59	0.52	0.37	0.92	1.64	1.37	1.26	3.36
PRETAX MARGIN %	18%	19%	19%	19%	19%	23%	26%	21%	22%
RETURN ON EQUITY %	9%	12%	11%	12%	13%	17%	14%	9%	9%
SALES % CHANGE	13%	13%	11%	8%	11%	28%	25%	6%	9%
SALES (MIL CHF	209	237	262	283	314	402	503	532	577
WEEKLY	**5 Apr**	**12 Apr**	**19 Apr**	**26 Apr**	**3 May**	**10 May**	**17 May**	**24 May**	**27 May**
DATAGRAPH RATING	63	60	64	62	62	63	65	60	59
AVG DAILY VOL (000)	84	79	77	75	71	68	65	56	54
UP DOWN VOLUME	2.4	2.1	2.1	1.8	1.7	1.4	1.6	1.1	1.1
ACCUM/DIST RATING	16	18	2	0	-6	8	41	26	26
RELATIVE STRENGTH	85	68	86	87	76	84	89	72	69
GROUP RANK	11	12	7	7	5	4	4	4	4

2024 Estimate	2025 Estimate
1.50 0%	2.04 36%

Earnings Growth Rate	Sales Growth Rate
2021-23 3% (9 Stability)	10%
2019-23 18% (14 Stability)	16%

COMP RATING 89 — SMR RATING B

INV T/O 1.2x 41				
DEBT %	2021-23	0.04%	0.03%	0.02%
TAX RATE	2021-23	13%	10%	10%
BACKLOG	2021-23	--	--	--
R & D	1.90%	BK VAL 5.06x '23		
DIV CHF	0.75 (0.9%)	DIV GR RT+8% (1)		
BETA	1.26(12.00)	ALPHA -0.03 (-0.01)		
2023 EMPLOYEES 2,006 (13%)				

0% from Pivot in 3 Weeks

Europe Long -5.58% in 1.6 WKS

OH -11% LOG (Fixed) PRICE

Strong EPS Rank

Strong technical profile. Up/Down Volume ratio of 1.1 and positive Acc/Dist Rating indicate accumulation. Good Group Rank of 4

Overall strong fundamental profile supported by healthy pretax margins. Double-digit EPS growth estimates for FY25

The stock is testing support at its 21-DMA after breaking out of a stage-one 53-week cup-with-handle base. Next support is at 50-DMA (CHF 83.22)

RS line is consolidating with good money flow



FINANCIALS	, 19	Sep, 19	Dec, 19	Mar, 20	Jun, 20	Sep, 20	Dec, 20	Mar, 21	Jun, 21	Sep, 21	Dec, 21	Mar, 22	Jun, 22	Sep, 22	Dec, 22	Mar, 23	Jun, 23	Sep, 23	Dec, 23	Mar, 24	Jun,
EPS (CHF)	.29		0.48		0.47		0.65		0.76		0.86		0.50		0.87		0.46		1.03		
EPS % CHANGE	1%		+9%		+62%		+35%		+62%		+32%		-34%		+1%		-8%		+18%		
EPS % SURPRISE	3%		+6.1%		+48.7%		+11.8%		+5.9%		-2.3%		-41.1%		-11.2%		-4.2%				
SALES (MIL CHF)	4.5		179.2		177.1		224.9		239.1		264.1		234.9		296.9		239.9		337.5		
SALES % CHANGE	1%		+4%		+32%		+25%		+35%		+17%		-2%		+12%		+2%		+14%		
MARGIN AFTER TAX	.2%		+18.8%		+18.5%		+20.1%		+22.2%		+23.3%		+15.6%		+21.6%		+14.4%		+22.9%		
FUNDS	135	135	145	155	203	187	221	215	252	285	541	579	583	596	626	645	675	684	682		

P/E	58
2024 Est.:	57.6
2025 Est.:	42.4
5-yr High:	108
5-yr Low:	33
vs Ind. Avg:	

PANARAY® 2024 WILLIAM O'NEIL + CO. INC.